S M Marks1, Y Hirsch-Moverman2, K Salcedo3, E A Graviss4, P Oh3, B Seaworth5, J Flood3, L Armstrong1, L Armitige5, S Mase1. 1. US Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA. 2. International Center for AIDS Care and Treatment Programs, Columbia University New York, New York, USA. 3. Division of Communicable Disease Control, Center for Infectious Diseases, California Department of Public Health, Richmond, California, USA. 4. Methodist Hospital Research Institute, Houston, Texas, USA. 5. Texas Department of State Health Services/University of Texas Health Science Center at Tyler, Texas, USA.
Abstract
OBJECTIVE: A population-based study of 135 multidrug-resistant tuberculosis (MDR-TB) patients reported to the Centers for Disease Control and Prevention (CDC) during 2005-2007 found 73% were hospitalized. We analyzed factors associated with hospitalization. METHODS: We assessed statistically significant multivariable associations with US in-patient TB diagnosis, frequency of hospitalization, length of hospital stay, and in-patient direct costs to the health care system. RESULTS: Of 98 hospitalized patients, 83 (85%) were foreign-born. Blacks, diabetics, or smokers were more likely, and patients with disseminated disease less likely, to receive their TB diagnosis while hospitalized. Patients aged ⩾65 years, those with the acquired immune-deficiency syndrome (AIDS), or with private insurance, were hospitalized more frequently. Excluding deaths, length of stay was greater for patients aged ⩾65 years, those with extensively drug-resistant TB (XDR-TB), those residing in Texas, those with AIDS, those who were unemployed, or those who had TB resistant to all first-line medications vs. others. Average hospitalization cost per XDR-TB patient (US$285 000) was 3.5 times that per MDR-TB patient (US$81 000), in 2010 dollars. Hospitalization episode costs for MDR-TB rank third highest and those for XDR-TB highest among the principal diagnoses. CONCLUSIONS: Hospitalization was common and remains a critical care component for patients who were older, had comorbidities, or required complex management due to XDR-TB. MDR-TB in-patient costs are among the highest for any disease.
OBJECTIVE: A population-based study of 135 multidrug-resistant tuberculosis (MDR-TB) patients reported to the Centers for Disease Control and Prevention (CDC) during 2005-2007 found 73% were hospitalized. We analyzed factors associated with hospitalization. METHODS: We assessed statistically significant multivariable associations with US in-patientTB diagnosis, frequency of hospitalization, length of hospital stay, and in-patient direct costs to the health care system. RESULTS: Of 98 hospitalized patients, 83 (85%) were foreign-born. Blacks, diabetics, or smokers were more likely, and patients with disseminated disease less likely, to receive their TB diagnosis while hospitalized. Patients aged ⩾65 years, those with the acquired immune-deficiency syndrome (AIDS), or with private insurance, were hospitalized more frequently. Excluding deaths, length of stay was greater for patients aged ⩾65 years, those with extensively drug-resistant TB (XDR-TB), those residing in Texas, those with AIDS, those who were unemployed, or those who had TB resistant to all first-line medications vs. others. Average hospitalization cost per XDR-TBpatient (US$285 000) was 3.5 times that per MDR-TBpatient (US$81 000), in 2010 dollars. Hospitalization episode costs for MDR-TB rank third highest and those for XDR-TB highest among the principal diagnoses. CONCLUSIONS: Hospitalization was common and remains a critical care component for patients who were older, had comorbidities, or required complex management due to XDR-TB. MDR-TB in-patient costs are among the highest for any disease.
Authors: Shanna Cox; Teresa Dean; Samuel F Posner; Denise J Jamieson; Kathryn M Curtis; Christopher H Johnson; Susan Meikle Journal: J Womens Health (Larchmt) Date: 2011-11-10 Impact factor: 2.681
Authors: A D Harries; S Satyanarayana; A M V Kumar; S B Nagaraja; P Isaakidis; S Malhotra; S Achanta; B Naik; N Wilson; R Zachariah; K Lönnroth; A Kapur Journal: Public Health Action Date: 2013-11-04
Authors: Suzanne M Marks; Jennifer Flood; Barbara Seaworth; Yael Hirsch-Moverman; Lori Armstrong; Sundari Mase; Katya Salcedo; Peter Oh; Edward A Graviss; Paul W Colson; Lisa Armitige; Manuel Revuelta; Kathryn Sheeran Journal: Emerg Infect Dis Date: 2014-05 Impact factor: 6.883
Authors: M V Aslam; K Owusu-Edusei; S M Marks; G R B Asay; R Miramontes; M Kolasa; C A Winston; P M Dietz Journal: Int J Tuberc Lung Dis Date: 2018-12-01 Impact factor: 2.373
Authors: Suzanne M Marks; Yael Hirsch-Moverman; Barbara Seaworth; Katya Salcedo; Edward A Graviss; Lori Armstrong; Lisa Armitige; Jennifer Flood; Sundari Mase Journal: Int J Tuberc Lung Dis Date: 2017-04-01 Impact factor: 2.373
Authors: Annie Belanger; Sapna Bamrah Morris; Richard Brostrom; David Yost; Neela Goswami; Margaret Oxtoby; Marisa Moore; Janice Westenhouse; Pennan M Barry; Neha S Shah Journal: J Clin Tuberc Other Mycobact Dis Date: 2019-01-27
Authors: Giorgi Kuchukhidze; Davit Baliashvili; Natalia Adamashvili; Ana Kasradze; Russell R Kempker; Matthew J Magee Journal: Open Forum Infect Dis Date: 2021-03-15 Impact factor: 3.835